Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;26(4):177–181. doi: 10.1002/clc.4960260406

Increased oxidative stress with elevated serum thioredoxin level in patients with coronary spastic angina

Kunihisa Miwa 2,5,✉, Chiharu Kishimoto 3, Hajime Nakamura 4, Toshinori Makita 2, Katsuhisa Ishii 2, Nobuaki Okuda 2, Ataru Taniguchi 1, Keisuke Shioji 3, Junji Yodoi 4, Shigetake Sasayama 3
PMCID: PMC6654305  PMID: 12708624

Abstract

Background: Increased oxidative stress has been implicated in the pathogenesis of coronary vasospasm. Thioredoxin (TRX) is a redox‐active protein that is known to be induced by oxidative stress.

Hypothesis: The serum TRX level may be high in patients with coronary vasospasm.

Methods: The serum TRX level was determined using an enzyme‐linked immunosorbent assay in 21 patients with the active stage of coronary spastic angina (CSA), in 18 patients with the inactive stage of CSA (iCSA), in 24 control subjects without coronary artery disease (Control), and in 20 patients with stable effort angina (SEA).

Results: Serum TRX levels (mean ± standard deviation ng/ml) were significantly higher in CSA (64 ± 44) than in iCSA (28 ± 26), in Control (34 ± 15), and in SEA (36 ± 16). In contrast, serum α‐tocopherol levels (mg/g lipids) were significantly lower in CSA (2.8 ± 0.7) than in Control (4.0 ± 1.2) and in SEA (3.2 ± 0.4). Current smoking was significantly more prevalent in CSA (76%) than in any of the other groups. No significant correlation was found between the serum level of TRX and α‐tocopherol in the study subjects. In nine patients with CSA, the serum TRX level decreased (93 ± 41 → 41 ±35 ng/ml) and the α‐tocopherol level increased (2.7 ± 0.6 → 3.2 ± 0.7 mg/g lipids) significantly under medication with calcium entry blockers after an at least 3‐month angina‐free period.

Conclusions: Patients with coronary spastic angina had a higher serum TRX level associated with a lower serum level of antioxidant vitamin E, with redox equilibrium appearing to be related to the disease activity of coronary vasospasm in these patients. Oxidative stress may be related to the genesis of coronary vasospasm.

Keywords: coronary spasm, coronary spastic angina, thioredoxin, oxidative stress, α‐tocopherol

Full Text

The Full Text of this article is available as a PDF (62.0 KB).

References

  • 1. Maseri A, Severi S, DeNes M, L'Abbate A, Chierchia S, Marzilli M, Ballestra AM, Parodi O, Biagini A, Distante A: “Variant” angina: One aspect of a continuous spectrum of vasospastic myocardial ischemia. Am J Cardiol 1978; 42: 1019–1035 [DOI] [PubMed] [Google Scholar]
  • 2. Yasue H, Omote S, Takizawa A, Nagao M: Coronary arterial spasm and its pathogenesis. A review. Circ Res 1983; 52 (suppl I): I‐147–152 [PubMed] [Google Scholar]
  • 3. Nobuyoshi M, Abe M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Shindo T, Kimura K, Nakamura T, Nakagawa Y, Shiode N, Sakamoto A, Kakura H, Iwasaki Y, Kim K, Kitaguchi S: Statistical analysis of clinical risk factors for coronary artery spasm: Identification of the most important determinant. Am Heart J 1992; 124: 32–38 [DOI] [PubMed] [Google Scholar]
  • 4. Sugiishi M, Takatsu F: Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993; 87: 76–79 [DOI] [PubMed] [Google Scholar]
  • 5. Yasue H, Takizawa A, Nagao M, Nishida S, Kubota J, Omote S, Takaoka K, Okumura K: Long‐term prognosis for patients with variant angina and influential factors. Circulation 1988; 78: 1–9 [DOI] [PubMed] [Google Scholar]
  • 6. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Yasue H: Cigarette smoking extract contracts isolated coronary porcine arteries by superoxide anion‐mediated degradation of EDRF. Am J Physiol 1994; 266: H874–H880 [DOI] [PubMed] [Google Scholar]
  • 7. Morrow JD, Frai B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA, Roberts LJ: Increase in circulating products of lipid peroxidation (F2‐isoprostanes) in smokers: Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198–1203 [DOI] [PubMed] [Google Scholar]
  • 8. Miwa K, Miyagi Y, Fujita M: Susceptibility of plasma low‐density lipoprotein to cupric ion‐induced peroxidation in patients with variant angina. J Am Coll Cardiol 1995; 26: 632–638 [DOI] [PubMed] [Google Scholar]
  • 9. Miwa K, Miyagi Y, Igawa A, Nakagawa K, Inoue H: Vitamin E deficiency in variant angina. Circulation 1996; 94: 14–18 [DOI] [PubMed] [Google Scholar]
  • 10. Kugiyama K, Motoyama T, Hirashima O, Ohgushi M, Soejima H, Misumi K, Kawano H, Miyao Y, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Yasue H: Vitamin C attenuates abnormal vasomotor reactivity in spasm coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 1998; 32: 103–109 [DOI] [PubMed] [Google Scholar]
  • 11. Motoyama T, Kawano H, Kugiyama K, Hirashima O, Ohgushi M, Tsunoda R, Moriyama Y, Miyao Y, Yoshimura M, Ogawa H, Yasue H: Vitamin E administration improves impairment of endothelium‐dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol 1998; 32: 1672–1679 [DOI] [PubMed] [Google Scholar]
  • 12. Nakamura H, Nakamura K, Yodoi J: Redox regulation of cellular activation. Ann Rev Immunol 1997; 15: 351–369 [DOI] [PubMed] [Google Scholar]
  • 13. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H, Yodoi J: ATL‐derived factor (ADF), an IL‐2 receptor/Tac inducer homologous to thioredoxin: Possible involvement of dithiol‐reduction in the IL‐2 receptor induction. EMBO J 1989; 8: 757–764 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Holmgren A: Thioredoxin and glutaredoxin systems. J Biol Chem 1989; 264: 13963–13966 [PubMed] [Google Scholar]
  • 15. Nakamura H, DeRosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, Holmgren A, Herzenberg LA: Elevation of plasma thioredoxin levels in HIV‐infected individuals. Int Immunol 1996; 8: 603–611 [DOI] [PubMed] [Google Scholar]
  • 16. Ericson ML, Horling J, Wendel HV, Holmgren A, Rosén A: Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res 1992; 11: 201–207 [PubMed] [Google Scholar]
  • 17. Rosén A, Lundman P, Carlsson M, Bhavani K, Srinivasa BR, Kjellstöm G, Nilsson K, Holmgen A: A CD4+ T cell line‐secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol 1995; 7: 623–633 [DOI] [PubMed] [Google Scholar]
  • 18. Miwa K, Fujita M, Ejiri M, Sasayama S: Comparative sensitivity of intra‐coronary injection of acetylcholine for the induction of coronary spasm in patients with various types of angina pectoris. Am Heart J 1990; 120: 544–550 [DOI] [PubMed] [Google Scholar]
  • 19. Friedwald WT, Levy RI, Frederickson DS: Estimation of the concentration of low‐density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–508 [PubMed] [Google Scholar]
  • 20. Nakamura H, Vaage J, Valen G, Padilla CA, Björnstedt M, Holmgren A: Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open‐heart surgery. Free Radic Biol Med 1998; 24: 1176–1186 [DOI] [PubMed] [Google Scholar]
  • 21. The Expert Committee : Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183–1197 [DOI] [PubMed] [Google Scholar]
  • 22. Shioji S, Kishimoto C, Nakamura H, Toyokuni S, Nakayama Y, Yodoi J, Sasayama S: Upregulation of thioredoxin (TRX) expression in giant cell myocarditis in rats. FEBS Lett 2000; 472: 109–113 [DOI] [PubMed] [Google Scholar]
  • 23. Selwyn AP, Kinlay S, Libby P, Ganz P: Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997; 95: 5–7 [DOI] [PubMed] [Google Scholar]
  • 24. Yasue H, Kugiyama K: Coronary artery spasm: Clinical features, pathogenesis and treatment In Coronary Artery Spasm (Ed. Yasue H.), p. 9–18. Tokyo: Axel Springer Japan Publishing, 2000. [Google Scholar]
  • 25. Miwa K: Vitamin E and coronary spasm In Coronary Artery Spasm (Ed. Yasue H.), p. 57–61. Tokyo: Axel Springer Japan Publishing, 2000. [Google Scholar]
  • 26. Kugiyama K, Yasue H, Okumura K, Ogawa H, Fujimoto K, Nakao K, Yoshimura M, Motoyama T, Inobe Y, Kawano H: Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996; 94: 266–272 [DOI] [PubMed] [Google Scholar]
  • 27. Ito A, Shimokawa H, Nakaike R, Fukui T, Sakata M, Takayanagi T, Egashira K, Takeshita A: Role of protein kinase C‐mediated pathway in the pathogenesis of coronary artery spasm in a swine model. Circulation 1994; 90: 2425–2431 [DOI] [PubMed] [Google Scholar]
  • 28. Ritchie ME: Nuclear factor‐κ B is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998; 98: 1707–1713 [DOI] [PubMed] [Google Scholar]
  • 29. Liao JK, Clark SL: Regulation of G‐protein and αi2 subunit expression by oxidized low‐density lipoprotein. J Clin Invest 1995; 95: 1457–1463 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Kugiyama K, Motoyama T, Doi H, Kawano H, Hirai N, Soejima H, Miyao Y, Takazoe K, Moriyama Y, Mizuno Y, Tsunoda R, Ogawa H, Sakamoto T, Sugiyama S, Yasue H: Improvement of endothelial vasomotor dysfunction by treatment with alpha‐tocopherol in patients with high remnant lipoprotein levels. J Am Coll Cardiol 1999; 33: 1512–1518 [DOI] [PubMed] [Google Scholar]
  • 31. Kugiyama K, Ohgushi M, Motoyama T, Hirashima O, Soejima H, Misumi K, Yoshimura M, Ogawa H, Sugiyama S, Yasue H: Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation 1998; 97: 2299–2301 [DOI] [PubMed] [Google Scholar]
  • 32. Prasad A, Andrews AP, Padder FA, Mohsin H, Quyyumi AA: Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J Am Coll Cardiol 1999; 34: 507–514 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES